An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-252/coif). The authors have no conflicts of interest to declare.
Frilling A, Clift AK, Kaemmerer D, Steinkraus KC, Schrader J, Wolter S, Drymousis P, Liedke MO, Hommann M, Habib N, Baum RP, Wasan H, Modlin IM, Izbicki JR.Frilling A, et al.Ann Surg. 2024 Dec 16. doi: 10.1097/SLA.0000000000006608. Online ahead of print.Ann Surg. 2024.PMID: 39676650
References
Sutcliffe R, Maguire D, Ramage J, et al. Management of neuroendocrine liver metastases. Am J Surg 2004;187:39-46. 10.1016/j.amjsurg.2003.04.007
-
DOI
-
PubMed
Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol 2012;2012:973946. 10.1155/2012/973946
-
DOI
-
PMC
-
PubMed
Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015;121:1172-86. 10.1002/cncr.28760
-
DOI
-
PubMed
Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014;15:e8-21. 10.1016/S1470-2045(13)70362-0
-
DOI
-
PubMed
Machairas N, Daskalakis K, Felekouras E, et al. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. 10.20524/aog.2021.0574
-
DOI
-
PMC
-
PubMed